Stryker R&D increased by 3.0% to $413.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 2.0%, from $405.00M to $413.00M. Over 4 years (FY 2021 to FY 2025), R&D shows an upward trend with a 7.1% CAGR.
Analysis
StatementIncome Statement
SectionOperating Expenses
CategoryGrowth
SignalContext dependent
VolatilityModerate
First reportedQ1 2013
Last reportedQ1 2026May 11, 2026
How to read this metric
Higher spending signals a commitment to innovation and future product launches, whereas significant cuts may indicate a shift toward short-term profitability.
Detailed definition
Research and development expenses represent the costs incurred to discover new products, improve existing technologies,...
Peer comparison
Highly comparable across pharmaceutical and medical device peers, where R&D intensity is a key metric for long-term valuation.
Metric ID:
research_and_developmentHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $310.00M | $306.00M | $331.00M | $413.00M | $351.00M | $364.00M | $326.00M | $339.00M | $346.00M | $353.00M | $350.00M | $368.00M | $363.00M | $377.00M | $358.00M | $405.00M | $407.00M | $410.00M | $401.00M | $413.00M |
| QoQ Change | — | -1.3% | +8.2% | +24.8% | -15.0% | +3.7% | -10.4% | +4.0% | +2.1% | +2.0% | -0.8% | +5.1% | -1.4% | +3.9% | -5.0% | +13.1% | +0.5% | +0.7% | -2.2% | +3.0% |
| YoY Change | — | — | — | — | +13.2% | +19.0% | -1.5% | -17.9% | -1.4% | -3.0% | +7.4% | +8.6% | +4.9% | +6.8% | +2.3% | +10.1% | +12.1% | +8.8% | +12.0% | +2.0% |
Range$306.00M – $413.00M
CAGR+6.2%
Avg YoY Growth+5.2%
Median YoY Growth+7.1%
Business Segments
| Segment | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|
| MedSurg and Neurotechnology: | $208.00M | $246.00M | $247.00M | $230.00M | $231.00M |
| Orthopaedics | $158.00M | — | — | — | — |
| Total | $405.00M | $407.00M | $410.00M | $401.00M | $413.00M |
R&D at Other Companies
Frequently Asked Questions
- What is Stryker's r&d?
- Stryker (SYK) reported r&d of $413.00M in Q1 2026.
- How has Stryker's r&d changed year-over-year?
- Stryker's r&d increased by 2.0% year-over-year, from $405.00M to $413.00M.
- What is the long-term trend for Stryker's r&d?
- Over 4 years (2021 to 2025), Stryker's r&d has grown at a 7.1% compound annual growth rate (CAGR), from $1.24B to $1.62B.
- What does r&d mean?
- The money spent on creating new products or improving existing ones to drive future growth.